Low Dose of Sugammadex vs Neostigmine and Glycopyrrolate for the Reversal of Rocuronium

Phase 4 Completed 144 enrolled Ciusss de L'Est de l'Île de Montréal

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The aim of this study is to compare the use of a low dose sugammadex and neostigmine combined to glycopyrrolate to reverse a rocuronium induced moderate neuromuscular blockade.

Timeline

Start: 2022-11-08
Primary completion: 2023-12-19
Completion: 2023-12-19

Outcome

Met primary endpoint

paper The median time to reach TOF ratio of ≥ 0.9 was significantly shorter in the sugammadex group (4.3 min, IQR: 3.2-6) PMID 41545820 ↗

paper compared to the neostigmine group (20.6 min, IQR: 10.1-21.3, p < 0.001). PMID 41545820 ↗

Publications

Hadj-Mimoune S, Morisson L, Ellassraoui S, Idrissi M, Quach M, Godin N, Oulehri W, Fortier LP, Verdonck O, Laferriere-Langlois P, Richebe P. Low dose of sugammadex versus neostigmine for reversal of rocuronium induced moderate neuromuscular block: a randomized controlled trial. BMC Anesthesiol. 2026 Jan 17;26(1):113. doi: 10.1186/s12871-025-03581-2.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Glycopyrrolate	Small molecule	7 ug/kg	—
Comparator	Neostigmine	Other / unclassified	50 ug/kg	—
Subject	Sugammadex	Other / unclassified	0.5 mg/kg	Intravenous

Indications

No indication recorded.